Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

YOUSUF A GAFFAR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1891798914
CMS profile
176932
Location
DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$178,008.56

188 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

YOUSUF A GAFFAR

NPI 1891798914 · CMS profile ID 176932

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891798914?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891798914?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891798914?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
YOUSUF A GAFFAR, NPI 1891798914, CMS profile ID 176932, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1891798914?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

188 matching records · $178,008.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 188 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–188 of 188.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $23.3005/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783645421 CMS
Rigel Pharmaceuticals, Inc. $88.9405/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854323925 CMS
Rigel Pharmaceuticals, Inc. $529.7505/12/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854329055 CMS
Rigel Pharmaceuticals, Inc. $4,000.0005/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854329751 CMS
Takeda Pharmaceuticals U.S.A., Inc. $20.9104/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819930591 CMS
Rigel Pharmaceuticals, Inc. $130.3504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854328601 CMS
Rigel Pharmaceuticals, Inc. $55.0004/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854328639 CMS
Rigel Pharmaceuticals, Inc. $90.0004/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854328787 CMS
Rigel Pharmaceuticals, Inc. $275.9804/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854328985 CMS
Rigel Pharmaceuticals, Inc. $272.2004/14/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854329061 CMS
E.R. Squibb & Sons, L.L.C. $15.1404/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783645411 CMS
Seagen Inc. $14.4103/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832174315 CMS
Rigel Pharmaceuticals, Inc. $4,000.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324921 CMS
Rigel Pharmaceuticals, Inc. $264.0203/15/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854325085 CMS
Exelixis Inc. $1,980.0003/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838864949 CMS
Rigel Pharmaceuticals, Inc. $297.4403/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324875 CMS
Janssen Pharmaceuticals, Inc $32.9403/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788796749 CMS
Rigel Pharmaceuticals, Inc. $115.8803/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324517 CMS
Rigel Pharmaceuticals, Inc. $2,000.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854323287 CMS
AstraZeneca Pharmaceuticals LP $300.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829500801 CMS
Exelixis Inc. $1,980.0003/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838864869 CMS
Eisai Inc. $19.5603/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817875505 CMS
Rigel Pharmaceuticals, Inc. $25.0003/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324397 CMS
Rigel Pharmaceuticals, Inc. $20.0003/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324515 CMS
Rigel Pharmaceuticals, Inc. $1,750.0003/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854323569 CMS
Rigel Pharmaceuticals, Inc. $316.9603/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324401 CMS
Rigel Pharmaceuticals, Inc. $55.0003/01/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324503 CMS
Rigel Pharmaceuticals, Inc. $18.8702/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854324675 CMS
Janssen Biotech, Inc. $14.7502/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788796747 CMS
Seagen Inc. $1,100.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832174299 CMS
Dova Pharmaceuticals $12.3302/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849747749 CMS
Rigel Pharmaceuticals, Inc. $1,750.0002/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854323345 CMS
AstraZeneca Pharmaceuticals LP $300.0001/31/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829366233 CMS
GENZYME CORPORATION $300.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843607641 CMS
AstraZeneca Pharmaceuticals LP $15.7501/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829315061 CMS
GENZYME CORPORATION $16.4501/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843607631 CMS
Myovant Sciences Inc. $19.0201/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834954837 CMS
Novartis Pharmaceuticals Corporation $99.7001/15/2021 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812684805 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $294,973.72 298
PY2020 $96,752.19 111
PY2021 $178,008.56 188
PY2022 $190,216.33 237
PY2023 $139,306.68 187
PY2024 $55,386.93 49
PY2025 $8,773.88 56

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $148,868.48 17
PY2023 Principal investigator $268,073.31 124
PY2022 Principal investigator $367,079.01 293
PY2021 Principal investigator $87,078.03 131
PY2019 Recipient $2,074.80 1
PY2019 Principal investigator $4,834.10 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,391.63 07/01/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079013530
Principal investigator 1 SOBI, INC $3,072.89 06/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH, LLC
PAC203/303 No dispute reported 06/30/2026 1141328717
Principal investigator 1 Incyte Corporation $956.00 04/15/2024 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1134700849
Principal investigator 1 Janssen Research & Development, LLC $12,074.12 03/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079013488
Principal investigator 1 Janssen Research & Development, LLC $12,354.44 03/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079013992
Principal investigator 1 Janssen Research & Development, LLC $5,178.96 03/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079014376
Principal investigator 1 Janssen Research & Development, LLC $9,810.22 03/18/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079014508
Principal investigator 1 Janssen Research & Development, LLC $7,527.27 03/04/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079013678
Principal investigator 1 Novartis Pharmaceuticals Corporation $715.32 02/08/2024 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, PA
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) No dispute reported 06/30/2026 1089697259
Principal investigator 1 Janssen Research & Development, LLC $8,597.13 02/05/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1079014392
Principal investigator 1 Incyte Corporation $20.26 02/01/2024 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1134700853
Principal investigator 1 Mirati Therapeutics, Inc. $3,710.71 02/01/2024 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1124762998
Principal investigator 1 AstraZeneca Pharmaceuticals LP $50,055.73 01/31/2024 Non-covered Recipient Entity
THE US ONCOLOGY NETWORK
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1110842349
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,687.80 01/15/2024 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1110839928
Principal investigator 1 Incyte Corporation $956.00 01/15/2024 Non-covered Recipient Entity
MARYLAND ONCOLOGY HEMATOLOGY, P.A.
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1134700851
Principal investigator 2 Mirati Therapeutics, Inc. $17,848.00 01/15/2024 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 No dispute reported 06/30/2026 1124763102
Principal investigator 1 Mirati Therapeutics, Inc. $1,912.00 01/15/2024 Non-covered Recipient Entity
Maryland Oncology Hematology, Pa
KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials No dispute reported 06/30/2026 1124764080